You just read:

Axovant's RVT-101 Phase 2b Completer Analysis Demonstrates Statistically Significant Benefits in Cognition and Function Through 48 Weeks

News provided by

Axovant Sciences Ltd.

Jul 22, 2015, 12:00 ET